Latest News
- ARCHIVIERT
Thursday - November 29, 2018
Group to take comprehensive range of portfolio, efficiency and structural measures
Bayer to strengthen core life science businesses while significantly enhancing productivity and profitability
Group plans to exit Animal Health business, the Consumer Health brands Coppertone™ and Dr. Scholl’s™, and sell its 60-percent interest in Currenta, a site services provider in Germany / Efficiency and structural measures set to enhance competitiveness and generate annual contributions of 2.6 billion euros as of 2022 including the expected synergies from the Monsanto acquisition / A portion of the contributions to be reinvested in core businesses / Total one-time costs expected at a factor of 1.7 times annual contributions / Core earnings per share expected to increase by around 1 euro to 6.80 euros in 2019, with a target of around 10 euros in 2022 / EBITDA margin before special items set to amount to over 30 percent in 2022 / Efficiency and structural measures expected to result in the reduction of around 12,000 of 118,200 jobs worldwide, a significant number of them in Germany » more
- ARCHIVIERT
Tuesday - November 27, 2018
Not intended for U.S. and UK Media
Bayer receives EU approval for its hemophilia A treatment Jivi®
The safety and efficacy profile of Jivi has been demonstrated in more than five years of clinical studies / Prophylaxis with Jivi enables sustained factor VIII concentrations in the blood over time » more
- ARCHIVIERT
Tuesday - November 27, 2018
Not intended for U.S. and UK Media
U.S. FDA approves Larotrectinib, the first TRK inhibitor, for patients with advanced solid tumors harboring an NTRK gene fusion
First treatment with a tumor-agnostic indication at the time of initial FDA approval / Larotrectinib approved under the brand name Vitrakvi® / 75% overall response rate (ORR) (95% CI, 61%, 85%) [22% complete response (CR) and 53% partial response (PR)] across various solid tumors in adults and children / Adverse events (AEs) of any grade observed in more than 20 percent of patients, regardless of attribution, included increased ALT (45%), increased AST (45%), anemia (42%), fatigue (37%), nausea (29%), dizziness (28%), cough (26%), vomiting (26%), constipation (23%), and diarrhea (22%) » more
- ARCHIVIERT
Wednesday - October 24, 2018
Not intended for U.S. and UK Media
Phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer meets primary endpoint
The safety and tolerability observed in the trial were consistent with previously published data on darolutamide » more
- ARCHIVIERT
Sunday - October 21, 2018
Not intended for U.S. and UK Media - ESMO 2018 Congress (European Society for Medical Oncology)
Expanded larotrectinib data confirm findings on efficacy and safety in adult and pediatric patients with TRK fusion cancer across various tumor types
Data presented across 122 adult and pediatric patients (55 patients from primary dataset plus supplementary dataset with 67 additional patients) with TRK fusion cancer across various tumor types / Integrated dataset on larotrectinib demonstrated high overall response rate of 81 percent (63 percent partial responses and 17 percent complete responses), per investigator assessment / For the initial 55 patients, ongoing responses at 12 months improved to 75 percent with longer follow-up; ongoing responses in the supplementary dataset were 81 percent at 12 months; median duration of response not reached at a respective follow-up of 17.6 and 7.4 months / 84 percent of responding patients in the integrated dataset remained on treatment or underwent surgery for curative intent / Larotrectinib showed favorable safety profile with majority of adverse events grade 1 or 2 / Larotrectinib is currently under regulatory review in the EU and U.S. » more
- ARCHIVIERT
Friday - October 12, 2018
Not intended for U.S. and UK Media
U.S. FDA approves Bayer’s Xarelto® for patients with coronary or peripheral artery disease
Xarelto, in combination with aspirin, is indicated to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease / Xarelto, in combination with aspirin, is the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated for this patient group / Approval in the U.S. follows regulatory clearance in both Europe and Canada » more
- ARCHIVIERT
Friday - September 21, 2018
Not intended for U.S. and UK Media
Bayer receives positive CHMP opinion for its hemophilia A treatment BAY94-9027
The safety and efficacy profile of BAY94-9027 has been demonstrated in more than five years of clinical studies / Prophylaxis with BAY94-9027 enables sustained factor VIII concentrations in the blood over time » more
- ARCHIVIERT
Friday - September 21, 2018
Not intended for U.S. and UK Media
Bayer’s Jivi® approved in Japan for hemophilia A » more
- ARCHIVIERT
Thursday - September 13, 2018
Stefan Oelrich to join Bayer Board of Management and head Pharmaceuticals Division
Dieter Weinand leaving the company as of November 1, 2018 / Contract extensions for Board of Management members Liam Condon and Dr. Hartmut Klusik » more
- ARCHIVIERT
Tuesday - September 4, 2018
LEO Pharma closes acquisition of Bayer’s prescription dermatology business in the United States » more
- ARCHIVIERT
Monday - September 3, 2018
Brazilian court rules that growers will continue to have access to glyphosate » more
- ARCHIVIERT
Thursday - August 30, 2018
Not intended for U.S. and UK Media
Bayer receives US approval for modern hemophilia A treatment Jivi® with a step-wise prophylaxis dosing regimen
Jivi’s extended half-life allows for twice-weekly initial dosing / May be adjusted to every five days and further individually adjusted to less or more frequent dosing » more
- ARCHIVIERT
Monday - August 27, 2018
New data presented at ESC Congress 2018:
Results of COMMANDER HF and MARINER studies with rivaroxaban published
Studies in very sick patient populations reaffirm and further strengthen the safety profile of rivaroxaban / Study results did not show a statistical difference in primary endpoints / COMMANDER HF study evaluated rivaroxaban in patients following an acute decompensation of heart failure and concomitant coronary artery disease / MARINER study evaluated rivaroxaban in acutely medically ill patients » more
- ARCHIVIERT
Monday - August 27, 2018
Not intended for U.S. and UK Media
Bayer submits European marketing authorization application for larotrectinib for the treatment of TRK fusion cancer » more
- ARCHIVIERT
Friday - August 24, 2018
Not intended for U.S. and UK Media
Bayer secures approval in the EU for Xarelto® (rivaroxaban) for patients with coronary or peripheral artery disease
Xarelto is the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated in combination with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in patients with coronary artery disease or symptomatic peripheral artery disease at high risk for ischemic events / Launch first expected in Germany » more
- ARCHIVIERT
Monday - August 20, 2018
Decision by Hamburg Regional Court in respect of reporting by WirtschaftsWoche » more
- ARCHIVIERT
Friday - August 17, 2018
Bayer rejects WirtschaftsWoche report on Dicamba lawsuits » more
- ARCHIVIERT
Thursday - August 16, 2018
Following completion of the divestment of Crop Science businesses to BASF
Bayer: Conditions for beginning Monsanto integration fulfilled
Legal remedies against jury verdict in California announced » more
- ARCHIVIERT
Wednesday - August 1, 2018
Not intended for U.S. and UK Media
Bayer receives approval of new treatment regimen for Eylea® in the EU
New treatment regimen could offer patients with neovascular age-related macular degeneration (AMD) extended proactive dosing already in the first year, while delivering strong visual gains / Data from ALTAIR study demonstrate sustainability of new approach in 57% of patients who extended their treatment interval to 12 weeks or more » more
- ARCHIVIERT
Tuesday - July 31, 2018
LEO Pharma to expand its lead in medical dermatology with acquisition of Bayer’s prescription dermatology unit
Significant step to bolster LEO Pharma’s role as a leading global dermatology company with its goal of helping 125 million patients by 2025 » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Thursday, February 25, 2021
Financial News Conference on the Full Year 2020 Results
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV